• About us
• Contact

Advertisement

Organisation › Details

LimmaTech Biologics AG

LimmaTech Biologics AG was incorporated following the acquisition of GlycoVaxyn by GSK in February 2015 and is a clinical-stage biopharmaceutical company, developing recombinant vaccines for major infectious diseases using a technology previously developed by GlycoVaxyn and now owned by GSK. The company is primarily dedicated to applying this technology to the development of bioconjugate vaccines and will also generate proprietary therapeutic products in areas outside of vaccines. *

 

	Start	2015-05-21 established
	Predecessor	GlycoVaxyn AG
	Industry	vaccine technology
	Industry 2	vaccine
	Person	Haas, Franz-Werner (LimmaTech Biologics 202307– CEO before CureVac + Sygnis Pharma + Lion BIoscience + Sirona Dental)
	Person 2	Dro, Philippe (LimmaTech Biologics 202307 Board Chair before CEO + Co-Founder before GlycoVaxyn CEO)
	Region	Schlieren ZH
	Country	Switzerland
	Street	3 Grabenstr.
	City	8952 Schlieren ZH
	Tel	+41-44-733-8585
		Address record changed: 2023-09-04
Basic data	Employees	n. a.
		* Document for »About Section«:
		Record changed: 2024-12-29

Advertisement

More documents for LimmaTech Biologics AG

• [1] Valneva S.E.. (8/1/24). "Press Release: Valneva and LimmaTech Enter into a Strategic Partnership to Accelerate the Development of the World’s Most Clinically Advanced Tetravalent Shigella Vaccine Candidate". Saint-Herblain & Schlieren....
• [2] LimmaTech Biologics AG. (12/19/23). "Press Release: LimmaTech Biologics Expands Vaccine Pipeline by Licensing AbVacc’s Innovative Vaccine Candidate Against Staphylococcus aureus". Schlieren & Rockville, MD....
• [3] LimmaTech Biologics AG. (10/9/23). "Press Release: LimmaTech Biologics Raises $37 Million Series A to Advance Its Pipeline of Vaccines Against Multidrug-Resistant Bacterial Infections". Schlieren....
• [4] LimmaTech Biologics AG. (7/20/23). "Press Release: LimmaTech Biologics Appoints Franz-Werner Haas as CEO to Lead Company into Next Stage of Corporate Growth". Schlieren....
• [5] LimmaTech Biologics AG. (7/20/23). "Press Release: GSK Grants LimmaTech Biologics License to Develop and Commercialize Shigella Vaccine". Schlieren....
• [6] GlycoEra AG. (1/5/21). "Press Release: GlycoEra AG Announces Its Incorporation and Welcomes Ganesh Kaundinya as Inaugural Member of the Board of Directors". Schlieren....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2025. Made in Germany.